LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

100.63 -4.21

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

99.95

Max

104.87

Schlüsselkennzahlen
By Trading Economics
Einkommen	-6.3M -53M
Verkäufe	2.8M 51M
EPS	-0.82
Gewinnspanne	-103.131
Angestellte	283
EBITDA	-7.6M -48M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+19.9% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-535M 7B
Vorheriger Eröffnungskurs	104.84
Vorheriger Schlusskurs	100.63

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

60 / 65.58 Unterstützung & Widerstand

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Dez. 2025, 22:13 UTC

Ergebnisse

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9. Dez. 2025, 21:40 UTC

Ergebnisse

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9. Dez. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9. Dez. 2025, 16:57 UTC

Wichtige Markttreiber

Clear Secure Rises on Medicare Identity Verification Contract

9. Dez. 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9. Dez. 2025, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings Stake in Lenovo Now at 32.34%

9. Dez. 2025, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9. Dez. 2025, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9. Dez. 2025, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9. Dez. 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9. Dez. 2025, 22:42 UTC

Ergebnisse

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9. Dez. 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9. Dez. 2025, 21:36 UTC

Ergebnisse

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9. Dez. 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9. Dez. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Reports Voting Results From Special Meeting of Hldrs

9. Dez. 2025, 20:26 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9. Dez. 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9. Dez. 2025, 19:52 UTC

Ergebnisse

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9. Dez. 2025, 19:17 UTC

Ergebnisse

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Dez. 2025, 17:11 UTC

Ergebnisse

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

19.9% Vorteil

12-Monats-Prognose

Durchschnitt 125.42 USD 19.9%

Hoch 142 USD

Tief 110 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.